{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:32:40Z","timestamp":1791415960190,"version":"4.3.3"},"reference-count":35,"publisher":"American Society of Hematology","issue":"4","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Data to guide evidence-based management of pregnant people with sickle cell disease (SCD) are limited. This international Delphi panel aimed to identify consensus among multidisciplinary experts for SCD management during pregnancy. The 2-round Delphi process used questionnaires exploring 7 topics (antenatal care, hydroxyurea use, transfusion, prevention of complications, treatment of complications, delivery and follow-up, and bottlenecks and knowledge gaps) developed by a steering committee. Thirteen panelists (hematologists, physiologists, obstetricians, maternal fetal medicine, and transfusion medicine physicians) from the United States, the United Kingdom, Turkey, and France completed the first survey; 12 panelists completed the second round. Anonymized responses were collected and summarized by a contract research organization (Akkodis Belgium). Consensus and strong consensus were predefined as 75% to 90% (9-10 of 12) and &amp;gt;90% (\u226511 of 12) of panelists, respectively, agreeing or disagreeing on a response to a predefined clinical scenario or statement. In several areas of SCD management, consensus was achieved: experts recommended performing at least monthly multidisciplinary antenatal follow-up, administering prophylactic aspirin for preeclampsia prevention between gestational weeks 12 and 36, initiating prophylactic transfusion therapy in certain cases, or choosing automated red blood cell exchange over other transfusion methods for patients with iron overload or severe acute chest syndrome. No consensus was reached on several topics including the prophylactic aspirin dose, indications for starting infection prophylaxis, routine use of prophylactic transfusions, or use of prophylactic transfusions for preventing fetal complications. These recommendations could inform clinical care for patients with SCD who are pregnant in the absence of large clinical trials involving this population; the identified knowledge gaps can orient future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011301","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T11:59:21Z","timestamp":1704974361000},"page":"1018-1029","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel"],"prefix":"10.1182","volume":"8","author":[{"given":"Deva","family":"Sharma","sequence":"first","affiliation":[{"name":"1Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilknur","family":"Kozano\u011flu","sequence":"additional","affiliation":[{"name":"2Department of Physiology, Faculty of Medicine, Ba\u015fkent University, Ankara, Turkey"},{"name":"3Adana Adult Bone Marrow Transplantation Center (CIC. 589), Apheresis Unit, Ba\u015fkent University, Yuregir, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4501-9982","authenticated-orcid":false,"given":"Kenneth I.","family":"Ataga","sequence":"additional","affiliation":[{"name":"4Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6045-0765","authenticated-orcid":false,"given":"Alexandra","family":"Benachi","sequence":"additional","affiliation":[{"name":"5Division of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Antoine B\u00e9cl\u00e8re Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris Saclay University Hospitals, Clamart, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0572-254X","authenticated-orcid":false,"given":"Selim","family":"B\u00fcy\u00fckkurt","sequence":"additional","affiliation":[{"name":"6Department of Obstetrics and Gynecology, Faculty of Medicine, \u00c7ukurova University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lanzkron","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8902-1283","authenticated-orcid":false,"given":"Hakan","family":"Ozdogu","sequence":"additional","affiliation":[{"name":"3Adana Adult Bone Marrow Transplantation Center (CIC. 589), Apheresis Unit, Ba\u015fkent University, Yuregir, Adana, Turkey"},{"name":"8Department of Hematology, Faculty of Medicine, Ba\u015fkent University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivan","family":"Pancham","sequence":"additional","affiliation":[{"name":"9Department of Haematology, Sandwell and West Birmingham Hospitals National Health Service Trust, West Bromwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-9752","authenticated-orcid":false,"given":"Lydia H.","family":"Pecker","sequence":"additional","affiliation":[{"name":"7Division of Hematology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD"},{"name":"10Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Robinson","sequence":"additional","affiliation":[{"name":"11Department of Women's Health, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safak","family":"Yilmaz Baran","sequence":"additional","affiliation":[{"name":"12Department of Obstetrics and Gynecology, Ba\u015fkent University, Dr. Turgut Noyan Application and Research Center, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Howard","sequence":"additional","affiliation":[{"name":"13Department of Clinical Haematology, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"issue":"9","key":"2024022713560886700_bib1","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3324\/haematol.2018.207357","article-title":"Emerging disease-modifying therapies for sickle cell disease","volume":"104","author":"Carden","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2024022713560886700_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.24235","article-title":"Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: the last 40 years","volume":"91","author":"Chaturvedi","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2024022713560886700_bib3","doi-asserted-by":"crossref","first-page":"e2019040","DOI":"10.4084\/mjhid.2019.040","article-title":"Sickle cell disease and pregnancy","volume":"11","author":"Jain","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"2024022713560886700_bib4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/hematology.2019000039","article-title":"Complications in pregnant women with sickle cell disease","volume":"2019","author":"Smith-Whitley","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"2024022713560886700_bib5","doi-asserted-by":"crossref","first-page":"E328","DOI":"10.1002\/ajh.25643","article-title":"Third trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD","volume":"94","author":"Asare","year":"2019","journal-title":"Am J Hematol"},{"key":"2024022713560886700_bib6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.critrevonc.2015.11.018","article-title":"Pregnancy and sickle cell disease: a review of the current literature","volume":"98","author":"Boga","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"2024022713560886700_bib7","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/bjh.17671","article-title":"Management of sickle cell disease in pregnancy. A British Society for Haematology guideline","volume":"194","author":"Oteng-Ntim","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2024022713560886700_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/(SICI)1096-8652(199902)60:2<148::AID-AJH12>3.0.CO;2-I","article-title":"Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature","volume":"60","author":"Diav-Citrin","year":"1999","journal-title":"Am J Hematol"},{"issue":"1","key":"2024022713560886700_bib9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/asheducation.V2015.1.436.3917688","article-title":"Optimizing hydroxyurea therapy for sickle cell anemia","volume":"2015","author":"Ware","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2024022713560886700_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ajh.26495","article-title":"Pregnancy outcomes with hydroxyurea use in women with sickle cell disease","volume":"97","author":"Kroner","year":"2022","journal-title":"Am J Hematol"},{"issue":"25","key":"2024022713560886700_bib11","doi-asserted-by":"crossref","first-page":"9383","DOI":"10.1080\/14767058.2022.2035713","article-title":"Impact of in utero opioid exposure on newborn outcomes: beyond neonatal opioid withdrawal syndrome","volume":"35","author":"Bailey","year":"2022","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"issue":"5","key":"2024022713560886700_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/pharmacy10050123","article-title":"Recent advances in sickle-cell disease therapies: a review of voxelotor, crizanlizumab, and L-glutamine","volume":"10","author":"Migotsky","year":"2022","journal-title":"Pharmacy (Basel)"},{"issue":"21","key":"2024022713560886700_bib13","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/blood-2015-06-649319","article-title":"Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis","volume":"126","author":"Malinowski","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2024022713560886700_bib14","doi-asserted-by":"crossref","first-page":"5S3","DOI":"10.1016\/S0248-8663(15)60002-9","article-title":"Recommandations fran\u00e7aises de prise en charge de la dr\u00e9panocytose de l\u2019adulte: actualisation 2015 [French guidelines for the management of adult sickle cell disease: 2015 update]","volume":"36","author":"Habibi","year":"2015","journal-title":"Rev Med Interne"},{"issue":"2","key":"2024022713560886700_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support","volume":"4","author":"Chou","year":"2020","journal-title":"Blood Adv"},{"key":"2024022713560886700_bib16","unstructured":"The American College of Obstetricians and Gynecologists\n          . Hemoglobinopathies in pregnancy. Accessed 5 December 2022. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2022\/08\/hemoglobinopathies-in-pregnancy."},{"issue":"1","key":"2024022713560886700_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/asheducation-2016.1.625","article-title":"Sickle cell disease: when and how to transfuse","volume":"2016","author":"Howard","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2024022713560886700_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.seminhematol.2018.04.010","article-title":"Sickle cell disease: translating clinical care to low-resource countries through international research collaborations","volume":"55","author":"Smart","year":"2018","journal-title":"Semin Hematol"},{"key":"2024022713560886700_bib19","doi-asserted-by":"crossref","first-page":"770640","DOI":"10.3389\/fphar.2021.770640","article-title":"Treating rare diseases in Africa: the drugs exist but the need is unmet","volume":"12","author":"Luzzatto","year":"2021","journal-title":"Front Pharmacol"},{"issue":"4","key":"2024022713560886700_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/NCM.0000000000000260","article-title":"Barriers to care for persons with sickle cell disease: the case manager's opportunity to improve patient outcomes","volume":"23","author":"Brennan-Cook","year":"2018","journal-title":"Prof Case Manag"},{"issue":"1","key":"2024022713560886700_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13063-017-2402-9","article-title":"Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach","volume":"19","author":"van der Graaf","year":"2018","journal-title":"Trials"},{"issue":"4","key":"2024022713560886700_bib22","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J\u00a0Adv Nurs"},{"issue":"8","key":"2024022713560886700_bib23","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0269216317690685","article-title":"Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review","volume":"31","author":"J\u00fcnger","year":"2017","journal-title":"Palliat Med"},{"issue":"4","key":"2024022713560886700_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"2","key":"2024022713560886700_bib25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/biomedicines11020597","article-title":"Outcomes of pregnancy in sickle cell disease patients: results from the prospective ESCORT-HU cohort study","volume":"11","author":"Habibi","year":"2023","journal-title":"Biomedicines"},{"issue":"suppl 1","key":"2024022713560886700_bib26","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2019-126529","article-title":"Hydroxyurea exposure throughout pregnancy in patients with sickle-cell disease: 4 case reports from European non-interventional, multicentric, prospective Escort-HU study","volume":"134","author":"Gellen-Dautremer","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2024022713560886700_bib27","first-page":"1046","article-title":"Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia","volume":"101","author":"Ballas","year":"2009","journal-title":"J\u00a0Natl Med Assoc"},{"issue":"4","key":"2024022713560886700_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/bdrb.20123","article-title":"NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea","volume":"80","author":"Liebelt","year":"2007","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"1","key":"2024022713560886700_bib29","doi-asserted-by":"crossref","first-page":"95.e1","DOI":"10.1016\/j.ajog.2020.07.023","article-title":"Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study","volume":"224","author":"Hastie","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"2024022713560886700_bib30","doi-asserted-by":"crossref","first-page":"e047949","DOI":"10.1136\/bmjopen-2020-047949","article-title":"Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy (PIPSICKLE): a randomised controlled trial (study protocol)","volume":"11","author":"Afolabi","year":"2021","journal-title":"BMJ Open"},{"issue":"22","key":"2024022713560886700_bib31","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJM198812013192204","article-title":"Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study","volume":"319","author":"Koshy","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024022713560886700_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s13063-020-4212-8","article-title":"Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial","volume":"21","author":"Oakley","year":"2020","journal-title":"Trials"},{"issue":"1","key":"2024022713560886700_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13063-023-07235-x","article-title":"Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): statistical and qualitative analysis plan for a randomised controlled feasibility trial","volume":"24","author":"Seed","year":"2023","journal-title":"Trials"},{"issue":"12","key":"2024022713560886700_bib34","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/j.1537-2995.2012.03659.x","article-title":"Lower alloimmunization rates in pediatric sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions","volume":"52","author":"Wahl","year":"2012","journal-title":"Transfusion"},{"issue":"4","key":"2024022713560886700_bib35","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1097\/HS9.0000000000000446","article-title":"Recommendations for pregnancy in rare inherited anemias","volume":"4","author":"Taher","year":"2020","journal-title":"Hemasphere"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/4\/1018\/2216085\/blooda_adv-2023-011301-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/4\/1018\/2216085\/blooda_adv-2023-011301-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T08:56:30Z","timestamp":1709024190000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/4\/1018\/506931\/Managing-sickle-cell-disease-and-related"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011301","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]}}}